Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Praful Ravi, MB BCHir, MRCP
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05617885CT.gov Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | — | Completed | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT04585932CT.gov Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | — | Withdrawn | — | — | — |
NCT04423211CT.gov Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | — | Recruiting | — | — | — |
NCT03951831CT.gov REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02020070CT.gov Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Degarelix (this asset) | Praful Ravi, MB BCHir, MRCP | P3 | BB · 68 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Degarelix
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Carcinoma | — | P3 | BBB · 73 |
| Prostate Cancer | — | P4 | BBB · 72 |
| Prostate Neoplasm | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Degarelix in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/degarelix-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →